AGIO Quote, Financials, Valuation and Earnings

Haemonetics has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of 9.79%. Agios Pharmaceuticals's return on equity of 71.3% beat Haemonetics's return on equity of 13.51%.

Agios Pharmaceuticals has a consensus price target of $57.29, signalling upside risk potential of 62.05%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 43.56%. Given that Agios Pharmaceuticals has higher upside potential than Haemonetics, analysts believe Agios Pharmaceuticals is more attractive than Haemonetics.

Agios Pharmaceuticals has a beta of 0.798, which suggesting that the stock is 20.182% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than Haemonetics quarterly revenues of $345.5M. Agios Pharmaceuticals's net income of $947.9M is higher than Haemonetics's net income of $33.8M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.11x while Haemonetics's PE ratio is 32.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 61.18x versus 2.92x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of 25.23%. Agios Pharmaceuticals's return on equity of 71.3% beat Pfizer's return on equity of 4.63%.

Agios Pharmaceuticals has a consensus price target of $57.29, signalling upside risk potential of 62.05%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that Agios Pharmaceuticals has higher upside potential than Pfizer, analysts believe Agios Pharmaceuticals is more attractive than Pfizer.

Agios Pharmaceuticals has a beta of 0.798, which suggesting that the stock is 20.182% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than Pfizer quarterly revenues of $17.7B. Agios Pharmaceuticals's net income of $947.9M is lower than Pfizer's net income of $4.5B. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.11x while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 61.18x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of 25.43%. Agios Pharmaceuticals's return on equity of 71.3% beat ResMed's return on equity of 23.76%.

Agios Pharmaceuticals has a consensus price target of $57.29, signalling upside risk potential of 62.05%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 9.49%. Given that Agios Pharmaceuticals has higher upside potential than ResMed, analysts believe Agios Pharmaceuticals is more attractive than ResMed.

Agios Pharmaceuticals has a beta of 0.798, which suggesting that the stock is 20.182% less volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than ResMed quarterly revenues of $1.2B. Agios Pharmaceuticals's net income of $947.9M is higher than ResMed's net income of $311.4M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.11x while ResMed's PE ratio is 30.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 61.18x versus 7.09x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of -40.91%. Agios Pharmaceuticals's return on equity of 71.3% beat Twist Bioscience's return on equity of -38.12%.

Agios Pharmaceuticals has a consensus price target of $57.29, signalling upside risk potential of 62.05%. On the other hand Twist Bioscience has an analysts' consensus of $51.81 which suggests that it could grow by 7.67%. Given that Agios Pharmaceuticals has higher upside potential than Twist Bioscience, analysts believe Agios Pharmaceuticals is more attractive than Twist Bioscience.

Agios Pharmaceuticals has a beta of 0.798, which suggesting that the stock is 20.182% less volatile than S&P 500. In comparison Twist Bioscience has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.223%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Twist Bioscience pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than Twist Bioscience quarterly revenues of $84.7M. Agios Pharmaceuticals's net income of $947.9M is higher than Twist Bioscience's net income of -$34.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.11x while Twist Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 61.18x versus 8.92x for Twist Bioscience. Usually stocks with elevated PS ratios are considered overvalued.